Search results
Results From The WOW.Com Content Network
Hypoxia-inducible factors (HIFs) are transcription factors that respond to decreases in available oxygen in the cellular environment, or hypoxia. [1] [2] They also respond to instances of pseudohypoxia, such as thiamine deficiency. [3] [4] Both hypoxia and pseudohypoxia leads to impairment of adenosine triphosphate (ATP) production by the ...
Erythropoietin (/ ɪ ˌ r ɪ θ r oʊ ˈ p ɔɪ. ɪ t ɪ n,-r ə-,-p ɔɪ ˈ ɛ t ɪ n,-ˈ iː t ɪ n /; [1] [2] [3] EPO), also known as erythropoetin, haematopoietin, or haemopoietin, is a glycoprotein cytokine secreted mainly by the kidneys in response to cellular hypoxia; it stimulates red blood cell production (erythropoiesis) in the bone marrow.
Endothelial PAS domain-containing protein 1 (EPAS1, also known as hypoxia-inducible factor-2alpha (HIF-2α)) is a protein that is encoded by the EPAS1 gene in mammals. It is a type of hypoxia-inducible factor, a group of transcription factors involved in the physiological response to oxygen concentration.
Hypoxia-inducible factor 1-alpha, also known as HIF-1-alpha, is a subunit of a heterodimeric transcription factor hypoxia-inducible factor 1 that is encoded by the HIF1A gene. [ 5 ] [ 6 ] [ 7 ] The Nobel Prize in Physiology or Medicine 2019 was awarded for the discovery of HIF.
From 2000 to 2006, EPO tests at the Olympics were conducted on both blood and urine. [30] [31] However, several compounds have been identified that can be taken orally to stimulate endogenous EPO production. Most of the compounds stabilize the hypoxia-inducible transcription factors which activate the EPO gene. The compounds include oxo ...
Hypoxia-inducible factor (HIF) is an evolutionarily conserved transcription factor [7] that allows the cell to respond physiologically to low concentrations of oxygen. [8] A class of prolyl hydroxylases which act specifically on HIF has been identified; [ 9 ] hydroxylation of HIF allows the protein to be targeted for degradation. [ 9 ]
No part of this book may be transmitted or reproduced in any form by any means without permission in writing from the publisher. Developmental Editor: John Barstow Editorial Director: Shay Totten Project Manager: Emily Foote Copy Editor: Nancy Crompton Fact-checker: Mary Fratini Book Designer: Peter Holm Printed in Canada on recycled paper.
Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are a novel class of oral medications developed for the treatment of anemia in chronic kidney disease (CKD). These drugs work by inhibiting hypoxia-inducible factor-proline dioxygenase (HIF prolyl-hydroxylase), which are responsible for the degradation of hypoxia-inducible factor ...